ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response

Jiang, Hongye; Ning, Gang; Wang, Yensheng; Lv, Weibiao*南方医科大学; 1
DISEASE MARKERS2021-6-11DOI: 10.1155/2021/5576683
23被引9阅读
引用收藏
分享

摘要

Background. N6-methyladenosine (m6A) modification plays an essential role in diverse key biological processes and may take part in the development and progression of hepatocellular carcinoma (HCC). Here, we systematically analyzed the expression profiles and prognostic values of 13 widely reported m6A modification-related genes in HCC. Methods. The mRNA expression of 13 m6A modification-related genes and clinical parameters of HCC patients were downloaded from TCGA, ICGC, GSE109211, and GSE78220. Univariate and LASSO analyses were used to develop risk signature. Time-dependent ROC was performed to assess the predictive accuracy and sensitivity of risk signature. Results. FTO, YTHDC1, YTHDC2, ALKBH5, KIAA1429, HNRNPC, METTL3, RBM15, YTHDF2, YTHDF1, and WTAP were significantly overexpressed in HCC patients. YTHDF1, HNRNPC, RBM15, METTL3, and YTHDF2 were independent prognostic factors for OS and DFS in HCC patients. Next, a risk signature was also developed and validated with five m6A modification-related genes in TCGA and ICGC HCC cohort. It could effectively stratify HCC patients into high-risk patients with shorter OS and DFS and low-risk patients with longer OS and DFS and showed good predictive efficiency in predicting OS and DFS. Moreover, significantly higher proportions of macrophages M0 cells, neutrophils, and Tregs were found to be enriched in HCC patients with high risk scores, while significantly higher proportions of memory CD4 T cells, gamma delta T cells, and naive B cells were found to be enriched in HCC patients with low scores. Finally, significantly lower risk scores were found at sorafenib treatment responders and anti-PD-1 immunotherapy responders compared to that in nonresponders, and anti-PD-1 immunotherapy-treated patients with lower risk scores had better OS than patients with higher risk scores. Conclusion. A risk signature developed with the expression of 5 m6A-related genes could improve the prediction of prognosis of HCC and correlated with sorafenib treatment and anti-PD-1 immunotherapy response.

学科与关键词

关键词
M(6)A RNA METHYLATIONCANCERCELLSPROGRESSIONMECHANISMSRECEPTOR
相关
加载中…
  • Expression and prognostic signatures of m6A-related lncRNAs in hepatocellular carcinoma
    Hao, Kenan; Li, Jincheng; Zhang, Youao; Zhao, Wei; Chen, Xiaojing; Xu, Jiabin; Tian, Ye; Li, Xinmin; Fen, Jianyu; He, Xiaofeng*Journal of Cancer Research and Clinical Oncology, 2023, 149(8): 4429-4441.被引 2
  • Prognostic Role and Potential Mechanisms of N6-methyladenosine-related Long Noncoding RNAs in Hepatocellular Carcinoma
    Dai, Tianxing; Li, Jing; Ye, Linsen; Yu, Haoyuan; Deng, Mingbin; Liu, Wei; Li, Hua; Yang, Yang*; Wang, Guoying*Journal of Clinical and Translational Hepatology, 2022, 10(2): 308-320.被引 2
  • Expression pattern and prognostic value of N6-methyladenosine RNA methylation key regulators in hepatocellular carcinoma
    Deng, Min; Fang, Lin; Li, Shao-Hua; Zhao, Rong-Ce; Mei, Jie; Zou, Jing-Wen; Wei, Wei; Guo, Rong-Ping*Mutagenesis, 2021, 36(5): 369-379.
查看全部 →

发表信息

论文状态
公开发表
期刊
DISEASE MARKERS
发表日期
2021-06-11
卷期
第 2021 卷
页码
5576683
DOI
10.1155/2021/5576683
语言
ENGLISH
期刊收录
NSL
期刊等级
4区
成果收录
SCIE
资助标注
China Postdoctoral Science Foundation [2020M682626]; Guangdong Basic and Applied Basic Research Foundation [2021A1515011117]; Regional Joint Youth Fund Project of Guangdong Province [2020A1515110976]

作者

  • J

    Jiang, Hongye (第一作者)

    1 · southern med univ

  • N

    Ning, Gang

    1

查看全部 4 位作者收起作者
  • W

    Wang, Yensheng

  • L

    Lv, Weibiao (通讯)

    1 · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417